Biological therapy for psoriatic arthritis: current state and future perspectives.

Autor: Boboryko D; Department of Physiology, Pomeranian Medical University, Szczecin, 70-111, Poland., Olejnik-Wojciechowska J; Department of Physiology, Pomeranian Medical University, Szczecin, 70-111, Poland., Baranowska M; Department of Physiology, Pomeranian Medical University, Szczecin, 70-111, Poland., Bratborska AW; Department of Dermatology and Venereology, Poznan University of Medical Sciences, Poznan, 60-355, Poland., Skórka P; Department of Physiology, Pomeranian Medical University, Szczecin, 70-111, Poland., Pawlik A; Department of Physiology, Pomeranian Medical University, Szczecin, 70-111, Poland. pawand@poczta.onet.pl.
Jazyk: angličtina
Zdroj: Rheumatology international [Rheumatol Int] 2024 Dec; Vol. 44 (12), pp. 2711-2725. Date of Electronic Publication: 2024 Sep 23.
DOI: 10.1007/s00296-024-05722-1
Abstrakt: Psoriatic arthritis is a medical condition that lies at the intersection of various fields of medicine, and its therapy always requires a comprehensive, holistic approach. Biological disease-modifying antirheumatic drugs (bDMARDs) constitute an extremely effective treatment method for PsA, provided that appropriate principles for patient qualification for the drug are followed, along with subsequent monitoring of the response to treatment. Based on their mechanisms of action, four main groups of bDMARDs used in PsA can be distinguished (TNF inhibitors, IL-12/23 and IL-23 inhibitors, IL-17 inhibitors, CTLA4 agonists). Clinical trials are ongoing in search of registration for additional bDMARDs, and the tasks for doctors and scientists worldwide include patient education, increasing treatment accessibility, and optimizing its costs.
Competing Interests: Declarations. Disclaimer: The authors state that no part of this narrative review is copied or published elsewhere, in whole or in part, in any language. Conflict of interest: All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: